Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Saroja Pharma Industries India Ltd. shows no current financial metrics, indicating a lack of operational performance or reporting issues. In contrast, its peers demonstrate varying degrees of growth, profitability, and valuation metrics, highlighting Saroja as a financially weak company compared to the sector.
Strong revenue growth (8.42% YoY) and solid profitability metrics (ROE of 16.13%, Profit Margin of 20.85%).
High ROE (21.76%) and solid growth trajectory (16.54% YoY revenue growth) with attractive valuation (PE of 15.50).